{"name":"Ismail Gögenur","slug":"ismail-g-genur","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"1 Cycle of Pembrolizumab","genericName":"1 Cycle of Pembrolizumab","slug":"1-cycle-of-pembrolizumab","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Additional Cycle of Pembrolizumab","genericName":"Additional Cycle of Pembrolizumab","slug":"additional-cycle-of-pembrolizumab","indication":"Melanoma","status":"phase_2"}]}],"pipeline":[{"name":"1 Cycle of Pembrolizumab","genericName":"1 Cycle of Pembrolizumab","slug":"1-cycle-of-pembrolizumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Additional Cycle of Pembrolizumab","genericName":"Additional Cycle of Pembrolizumab","slug":"additional-cycle-of-pembrolizumab","phase":"phase_2","mechanism":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.","indications":["Melanoma","Non-small cell lung cancer","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQQW5CWFg5NEVpeGllajN6WWFFZzlPT1MyZi1keHlJM0p6eVhaLXlIZ3JfNVo3N0Y0aWE4SEdCUExtMGJweUU5cF8zMzZDSzZPNHg2cTh6NEM1c1VOQ1BPV3FsRGd4cDl1NEZqR1gzTlY4SW9uVF9VcmlFaTdnaDFvMzY1NmlfWVlzcHpJT3hrN2VDTnc?oc=5","date":"2025-09-30","type":"pipeline","source":"Medical Xpress","summary":"AI tool reduces complications and readmissions after colorectal cancer surgery - Medical Xpress","headline":"AI tool reduces complications and readmissions after colorectal cancer surgery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5qX1dhMDB2dk9NWV83Um91VmxZTzNpTGJKM2VUSnJBY1dYS092dHp3VXl0X2Fua01kcFZvdksxOUQ2cnRvaUNlbEF3NHQyRjAzeWZRRmh0Sm1UeUlSWXln?oc=5","date":"2025-09-18","type":"pipeline","source":"Nature","summary":"Clinical implementation of an AI-based prediction model for decision support for patients undergoing colorectal cancer surgery - Nature","headline":"Clinical implementation of an AI-based prediction model for decision support for patients undergoing colorectal cancer s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOTlprYVkzaVE4cUJqWkcyVzBFR2Z4ajJxOGNGTnc4MVBseHZRZmdBNVRVb3ZZYzVUVjd1VExjQ3A4cTVjVnNvQzdZNTZIUzNERHBMOHZvS3hZNUg0d2lXM1Zfa2FFcmFUMnpZbW9IbVhPTnJVMHUwc0tqdGNKNWxwU012LUJoUUNDdE9qM0RjSEVMRnhUN0ZTVlVVYjZSQlhnR2RrcVVxVW81SzBSSWV3a1pZWQ?oc=5","date":"2025-01-23","type":"pipeline","source":"Novo Nordisk Fonden","summary":"Cancer researcher excelling in artificial intelligence receives major prize - Novo Nordisk Fonden","headline":"Cancer researcher excelling in artificial intelligence receives major prize","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNRUJzSXdQUnJsYVVkYlRicWQxV083MGoyb2VfZEYwVW13dFNkRmJjQUYtUm9xMVo0NWxSOTlZZFFtbzlqQUxlT1V2NExNbDlrNmdwNERlLVBhbGltNlBWQy1HV2RXY0IyZGlxRDZMelZIYTRuZ08wR1NGT3ZBTVRfRlp6ZTd4U1VVaDh1d3RHRmlQeV9FNVdJZ0x5Y2NDYUUydDV1c3JRMEgyVm16aFo0SzM5NXY?oc=5","date":"2020-05-22","type":"pipeline","source":"med.uio.no","summary":"Digital public defence: Jens Marius Næsgaard - med.uio.no","headline":"Digital public defence: Jens Marius Næsgaard","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}